{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:01:46Z","timestamp":1771988506690,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3226,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in subjects coinfected with HIV. Tenofovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) are licensed for the treatment of HIV-1 and HBV infection, respectively, but both have<\/jats:bold>\n                                 <jats:bold>\n                                    in vivo\n                                 <\/jats:bold>\n                                 <jats:bold>and<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>\n                                 <jats:bold>activity against HBV. This study evaluated the anti-HBV activity of TDF compared to ADV in HIV\/HBV-coinfected subjects. ACTG A5127 was a prospective randomized, double-blind, placebo-controlled trial of daily 10 mg of ADV versus 300 mg of TDF in subjects with HBV and HIV coinfection on stable ART, with serum HBV DNA \u2265 100,000 copies\/mL, and plasma HIV-1 RNA \u2264 10,000 copies\/mL. This study closed early based on results of a prespecified interim review, as the primary noninferiority end point had been met without safety issues. Fifty-two subjects were randomized. At baseline, 73% of subjects had a plasma HIV-1 RNA &lt; 50 copies\/mL, 86% were HBeAg positive, 94% were 3TC resistant, median serum ALT was 52 IU\/L, and 98% had compensated liver disease. The mean time-weighted average change in serum HBV DNA from baseline to week 48 (DAVG48) was \u22124.44 log10 copies\/mL for TDF and \u22123.21 log10 copies\/mL for ADV. There was no difference in toxicity between the 2 treatment arms, with 11 subjects (5 ADV and 6 TDF) experiencing elevations of serum ALT on treatment.<\/jats:bold>\n                                 <jats:bold>\n                                    In conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs are safe and efficacious for patients coinfected with HBV and HIV.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21388","type":"journal-article","created":{"date-parts":[[2006,10,20]],"date-time":"2006-10-20T19:18:34Z","timestamp":1161371914000},"page":"1110-1116","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":148,"title":["Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127"],"prefix":"10.1097","volume":"44","author":[{"given":"Marion G.","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly","family":"Alston-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol L.","family":"Brosgart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20241201","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/infdis\/163.3.454","article-title":"Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.","volume":"163","author":"Hadler","year":"1991","journal-title":"J Infect Dis"},{"key":"R2-7-20241201","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jurban\/jth085","article-title":"Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities.","volume":"81","author":"Solomon","year":"2004","journal-title":"J Urban Health"},{"issue":"Suppl 4","key":"R3-7-20241201","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2516.2004.00997.x","article-title":"Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia.","volume":"10","author":"Goedert","year":"2004","journal-title":"Haemophilia"},{"key":"R4-7-20241201","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2003-39951","article-title":"Hepatitis B in the human immunodeficiency virusinfected patient: epidemiology, natural history, and treatment.","volume":"23","author":"Thio","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R5-7-20241201","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S0074-02762005000100002","article-title":"Prevalence of hepatitisB surface antigen among blood donors and human immunodeficiency virusinfected patients in Jos, Nigeria.","volume":"100","author":"Uneke","year":"2005","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"R6-7-20241201","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Longterm incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virusinfected patients.","volume":"30","author":"Benhamou","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R7-7-20241201","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigennegative chronic hepatitis B.","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-7-20241201","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B.","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R9-7-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B.","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"R10-7-20241201","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jama.292.2.251","article-title":"Treatment for adult HIV infection: 2004 recommendations of the International AIDS SocietyUSA Panel.","volume":"292","author":"Yeni","year":"2004","journal-title":"JAMA"},{"key":"R11-7-20241201","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/135965350400900311","article-title":"In vitro susceptibility of lamivudineresistant hepatitis B virus to adefovir and tenofovir.","volume":"9","author":"Lada","year":"2004","journal-title":"Antivir Ther"},{"key":"R12-7-20241201","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudineresistant hepatitis B virus infection.","volume":"40","author":"van Bommel","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R13-7-20241201","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1086\/345770","article-title":"Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virushepatitis B viruscoinfected individuals for whom interferonalpha and lamivudine therapy have failed.","volume":"186","author":"Ristig","year":"2002","journal-title":"J Infect Dis"},{"key":"R14-7-20241201","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV1 and lamivudineresistant hepatitis B virus: an openlabel pilot study.","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"R16-7-20241201","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2893.2000.00210.x","article-title":"Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, LFMAU, DAPD, penciclovir and lobucavir.","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"key":"R17-7-20241201","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","article-title":"Tenofovir for patients with lamivudineresistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.","volume":"44","author":"van Bommel","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R18-7-20241201","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.21055","article-title":"Antihepatitis B virus efficacy of tenofovir disoproxil fumarate in HIVinfected patients.","volume":"43","author":"Benhamou","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R19-7-20241201","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/hep.510280629","article-title":"Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. see comments.","volume":"28","author":"Xiong","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R20-7-20241201","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/aid.2006.22.333","article-title":"Higher risk of hyperglycemia in HIVinfected patients treated with didanosine plus tenofovir.","volume":"22","author":"GarciaBenayas","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R21-7-20241201","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B.","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"R22-7-20241201","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV coinfected patients.","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"R24-7-20241201","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.aids.0000163948.62176.e7","article-title":"Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIVHBV International Panel.","volume":"19","author":"Soriano","year":"2005","journal-title":"AIDS"},{"key":"R25-7-20241201","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/01.aids.0000189563.79976.05","article-title":"Risk of selecting K65R in antiretroviralnaive HIVinfected individuals with chronic hepatitis B treated with adefovir.","volume":"19","author":"Sheldon","year":"2005","journal-title":"AIDS"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21388","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200611000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:04:17Z","timestamp":1733058257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200611000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21388","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}